Gilead Sciences (FRA:GIS) FFO


FRA:GIS Gilead Sciences Inc FRA:GIS
75 GF Score
Price €108.26
GF Value €81.25
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences FFO?

FFO (Funds from operations) only applies to REITs.

FRA:GIS
75GF Score
Gilead Sciences Inc FRA:GIS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gilead Sciences (FRA:GIS) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of €108.26 is trading 33.2% above its estimated GF Value™ of €81.25. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for FRA:GIS:

  • FFO:
  • GF Value™: €81.25 vs. price of €108.26 (33.2% above fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score

Get the complete analysis for FRA:GIS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€108.26
Price
€81.25
GF Value